HIV-2 (AA 390-702) anticorps

N° du produit ABIN111771

Cité dans 1 publication. Cet anticorps anti-HIV-2 Monoclonal Souris (Clone BDI411) (ABIN111771) détecte spécifiquement HIV-2 dans WB, EIA et IP. L’anticorps est réactif avec des échantillons de Human Immunodeficiency Virus (HIV).

Aperçu rapide pour HIV-2 (AA 390-702) anticorps (ABIN111771)

Antigène: HIV-2

Reactivité: Human Immunodeficiency Virus (HIV)

Hôte: Souris

Clonalité: Monoclonal

Conjugué: Inconjugué

Application: Western Blotting (WB), Enzyme Immunoassay (EIA), Immunoprecipitation (IP)

Clone: BDI411

Détail du produit

Épitope: AA 390-702

Purification: Protein G Chromatography.

Immunogène: Recombinant gp36, amino acids 390-702 (Art. No. BIN07)

Isotype: IgG2a

Information d'application

Indications d'application: Suitable for use in Western blot (1: 1,000), ELISA (1: 500) and Immunoprecipitation.
Other applications not tested.
Optimal dilutions are dependent on conditions and should be determined by the user.

Restrictions: For Research Use only

Stockage

Concentration: 1.0 mg/mL

Buffer: 1X PBS, pH 7.2 containing 0.01 % Sodium Azide as preservative.

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Conseil sur la manipulation: Avoid repeated freezing and thawing.

Stock: -20 °C

Référence

Dufrasne, Lucchetti, Martin, André, Dessilly, Kabamba, Goubau, Ruelle: "Modulation of the NF-κB signaling pathway by the HIV-2 envelope glycoprotein and its incomplete BST-2 antagonism." dans: Virology, Vol. 513, pp. 11-16, (2017) (PubMed).

Détail du antigène

Antigène: HIV-2

Classe de substances: Virus

Sujet: HIV2 infections at present, are predominantly found in west Africa where it is the dominant form of HIV. Both HIV1 and HIV2 have the same modes of transmission and are associated with similar opportunistic infections and AIDS. In persons infected with HIV2, immunodeficiency seems to develop more slowly and to be milder, but as the disease advances, HIV2 infectiousness seems to increase. Little is known about the best approach to the clinical treatment and care of patients infected with HIV2. Some drugs used to treat HIV1 are ineffective. HIV1 and HIV2 have similar gag (viral core) and pol (polymerase) regions, they have relatively dissimilar env (envelope) regions. Owing to this lack of homology in the envelope region, there is little serologic cross-reactivity of the antibodies directed against the envelope antigens of both HIV1 and HIV2. The env gp36 ectodomain is highly conserved and elicits a type-specific antibody response. Hence, most licensed diagnostic assays incorporate gp36-derived antigens to detect HIV2 specific antibodies. It is becoming important to differentiate between single infection with either HIV1 or HIV2 and dual infection.Synonyms: HIV2, Human immunodeficiency virus type 2